nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxycodone—CYP3A5—Beclomethasone—psoriasis	0.0915	0.137	CbGbCtD
Oxycodone—CYP2D6—Hydroxyurea—psoriasis	0.0425	0.0639	CbGbCtD
Oxycodone—CYP3A7—Hydrocortisone—psoriasis	0.039	0.0586	CbGbCtD
Oxycodone—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.039	0.0586	CbGbCtD
Oxycodone—CYP3A7—Cyclosporine—psoriasis	0.0368	0.0553	CbGbCtD
Oxycodone—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0368	0.0553	CbGbCtD
Oxycodone—CYP3A5—Mycophenolate mofetil—psoriasis	0.0364	0.0547	CbGbCtD
Oxycodone—CYP3A4—Calcitriol—psoriasis	0.0318	0.0478	CbGbCtD
Oxycodone—CYP3A5—Hydrocortisone—psoriasis	0.0292	0.0439	CbGbCtD
Oxycodone—CYP3A5—Cyclosporine—psoriasis	0.0276	0.0415	CbGbCtD
Oxycodone—CYP2D6—Cholecalciferol—psoriasis	0.0258	0.0387	CbGbCtD
Oxycodone—CYP3A4—Methoxsalen—psoriasis	0.0247	0.0372	CbGbCtD
Oxycodone—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0242	0.0364	CbGbCtD
Oxycodone—CYP3A7—Dexamethasone—psoriasis	0.0242	0.0364	CbGbCtD
Oxycodone—CYP3A5—Dexamethasone—psoriasis	0.0182	0.0273	CbGbCtD
Oxycodone—CYP2D6—Cyclosporine—psoriasis	0.0169	0.0254	CbGbCtD
Oxycodone—CYP3A4—Cholecalciferol—psoriasis	0.0164	0.0246	CbGbCtD
Oxycodone—CYP3A4—Mycophenolate mofetil—psoriasis	0.0142	0.0213	CbGbCtD
Oxycodone—CYP3A4—Triamcinolone—psoriasis	0.0142	0.0213	CbGbCtD
Oxycodone—CYP3A4—Betamethasone—psoriasis	0.0122	0.0183	CbGbCtD
Oxycodone—CYP3A4—Prednisolone—psoriasis	0.012	0.0181	CbGbCtD
Oxycodone—CYP3A4—Hydrocortisone—psoriasis	0.0114	0.0171	CbGbCtD
Oxycodone—CYP3A4—Prednisone—psoriasis	0.0114	0.0171	CbGbCtD
Oxycodone—CYP2D6—Dexamethasone—psoriasis	0.0111	0.0168	CbGbCtD
Oxycodone—CYP3A4—Cyclosporine—psoriasis	0.0108	0.0162	CbGbCtD
Oxycodone—CYP3A4—Dexamethasone—psoriasis	0.00709	0.0107	CbGbCtD
Oxycodone—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.000785	0.071	CbGpPWpGaD
Oxycodone—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000651	0.0588	CbGpPWpGaD
Oxycodone—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000607	0.0549	CbGpPWpGaD
Oxycodone—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000567	0.0513	CbGpPWpGaD
Oxycodone—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000403	0.0365	CbGpPWpGaD
Oxycodone—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000326	0.0295	CbGpPWpGaD
Oxycodone—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000321	0.0291	CbGpPWpGaD
Oxycodone—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000264	0.0239	CbGpPWpGaD
Oxycodone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000264	0.0238	CbGpPWpGaD
Oxycodone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000235	0.0213	CbGpPWpGaD
Oxycodone—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000232	0.021	CbGpPWpGaD
Oxycodone—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000191	0.0173	CbGpPWpGaD
Oxycodone—OPRD1—G alpha (i) signalling events—HCAR2—psoriasis	0.00019	0.0171	CbGpPWpGaD
Oxycodone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000167	0.0151	CbGpPWpGaD
Oxycodone—OPRK1—G alpha (i) signalling events—HCAR2—psoriasis	0.000166	0.015	CbGpPWpGaD
Oxycodone—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000165	0.0149	CbGpPWpGaD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000151	0.0136	CbGpPWpGaD
Oxycodone—OPRM1—G alpha (i) signalling events—HCAR2—psoriasis	0.000141	0.0127	CbGpPWpGaD
Oxycodone—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.00014	0.0127	CbGpPWpGaD
Oxycodone—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000138	0.0125	CbGpPWpGaD
Oxycodone—OPRM1—TCR Signaling Pathway—REL—psoriasis	0.000136	0.0123	CbGpPWpGaD
Oxycodone—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000136	0.0123	CbGpPWpGaD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000132	0.012	CbGpPWpGaD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000117	0.0106	CbGpPWpGaD
Oxycodone—OPRM1—IL4-mediated signaling events—SOCS1—psoriasis	0.000117	0.0106	CbGpPWpGaD
Oxycodone—OPRD1—GPCR ligand binding—HCAR2—psoriasis	0.000115	0.0104	CbGpPWpGaD
Oxycodone—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	0.000114	0.0103	CbGpPWpGaD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000112	0.0101	CbGpPWpGaD
Oxycodone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000109	0.0099	CbGpPWpGaD
Oxycodone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000108	0.00977	CbGpPWpGaD
Oxycodone—OPRM1—IL4-mediated signaling events—IL10—psoriasis	0.000105	0.00947	CbGpPWpGaD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000102	0.00926	CbGpPWpGaD
Oxycodone—OPRM1—IL4-mediated signaling events—IL4—psoriasis	0.000102	0.00921	CbGpPWpGaD
Oxycodone—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000101	0.00917	CbGpPWpGaD
Oxycodone—OPRK1—GPCR ligand binding—HCAR2—psoriasis	0.000101	0.0091	CbGpPWpGaD
Oxycodone—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.0001	0.00905	CbGpPWpGaD
Oxycodone—OPRD1—G alpha (i) signalling events—CCL20—psoriasis	9.85e-05	0.00891	CbGpPWpGaD
Oxycodone—Anxiety—Dexamethasone—psoriasis	8.96e-05	0.000277	CcSEcCtD
Oxycodone—Anxiety—Betamethasone—psoriasis	8.96e-05	0.000277	CcSEcCtD
Oxycodone—Vomiting—Mycophenolic acid—psoriasis	8.93e-05	0.000276	CcSEcCtD
Oxycodone—Discomfort—Dexamethasone—psoriasis	8.89e-05	0.000275	CcSEcCtD
Oxycodone—Discomfort—Betamethasone—psoriasis	8.89e-05	0.000275	CcSEcCtD
Oxycodone—Dyspepsia—Hydrocortisone—psoriasis	8.88e-05	0.000275	CcSEcCtD
Oxycodone—Haemoglobin—Methotrexate—psoriasis	8.88e-05	0.000274	CcSEcCtD
Oxycodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.87e-05	0.00803	CbGpPWpGaD
Oxycodone—Rash—Mycophenolic acid—psoriasis	8.85e-05	0.000274	CcSEcCtD
Oxycodone—Dermatitis—Mycophenolic acid—psoriasis	8.84e-05	0.000273	CcSEcCtD
Oxycodone—Pain—Prednisolone—psoriasis	8.84e-05	0.000273	CcSEcCtD
Oxycodone—Haemorrhage—Methotrexate—psoriasis	8.83e-05	0.000273	CcSEcCtD
Oxycodone—Hepatitis—Methotrexate—psoriasis	8.83e-05	0.000273	CcSEcCtD
Oxycodone—Urticaria—Mycophenolate mofetil—psoriasis	8.8e-05	0.000272	CcSEcCtD
Oxycodone—Headache—Mycophenolic acid—psoriasis	8.79e-05	0.000272	CcSEcCtD
Oxycodone—Decreased appetite—Hydrocortisone—psoriasis	8.77e-05	0.000271	CcSEcCtD
Oxycodone—Pharyngitis—Methotrexate—psoriasis	8.77e-05	0.000271	CcSEcCtD
Oxycodone—Body temperature increased—Mycophenolate mofetil—psoriasis	8.76e-05	0.000271	CcSEcCtD
Oxycodone—Abdominal pain—Mycophenolate mofetil—psoriasis	8.76e-05	0.000271	CcSEcCtD
Oxycodone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	8.76e-05	0.00792	CbGpPWpGaD
Oxycodone—Urinary tract disorder—Methotrexate—psoriasis	8.72e-05	0.00027	CcSEcCtD
Oxycodone—Gastrointestinal disorder—Hydrocortisone—psoriasis	8.71e-05	0.000269	CcSEcCtD
Oxycodone—Fatigue—Hydrocortisone—psoriasis	8.7e-05	0.000269	CcSEcCtD
Oxycodone—Urethral disorder—Methotrexate—psoriasis	8.66e-05	0.000268	CcSEcCtD
Oxycodone—Musculoskeletal discomfort—Triamcinolone—psoriasis	8.66e-05	0.000268	CcSEcCtD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	8.65e-05	0.00782	CbGpPWpGaD
Oxycodone—OPRK1—G alpha (i) signalling events—CCL20—psoriasis	8.64e-05	0.00781	CbGpPWpGaD
Oxycodone—Pain—Hydrocortisone—psoriasis	8.63e-05	0.000267	CcSEcCtD
Oxycodone—Oedema—Betamethasone—psoriasis	8.62e-05	0.000266	CcSEcCtD
Oxycodone—Oedema—Dexamethasone—psoriasis	8.62e-05	0.000266	CcSEcCtD
Oxycodone—Anaphylactic shock—Betamethasone—psoriasis	8.62e-05	0.000266	CcSEcCtD
Oxycodone—Anaphylactic shock—Dexamethasone—psoriasis	8.62e-05	0.000266	CcSEcCtD
Oxycodone—Insomnia—Triamcinolone—psoriasis	8.6e-05	0.000266	CcSEcCtD
Oxycodone—Infection—Dexamethasone—psoriasis	8.57e-05	0.000265	CcSEcCtD
Oxycodone—Infection—Betamethasone—psoriasis	8.57e-05	0.000265	CcSEcCtD
Oxycodone—Ill-defined disorder—Prednisone—psoriasis	8.54e-05	0.000264	CcSEcCtD
Oxycodone—Paraesthesia—Triamcinolone—psoriasis	8.53e-05	0.000264	CcSEcCtD
Oxycodone—Feeling abnormal—Prednisolone—psoriasis	8.52e-05	0.000263	CcSEcCtD
Oxycodone—Visual impairment—Methotrexate—psoriasis	8.51e-05	0.000263	CcSEcCtD
Oxycodone—OPRM1—GPCR ligand binding—HCAR2—psoriasis	8.51e-05	0.00769	CbGpPWpGaD
Oxycodone—Anaemia—Prednisone—psoriasis	8.5e-05	0.000263	CcSEcCtD
Oxycodone—Shock—Dexamethasone—psoriasis	8.48e-05	0.000262	CcSEcCtD
Oxycodone—Shock—Betamethasone—psoriasis	8.48e-05	0.000262	CcSEcCtD
Oxycodone—Dyspnoea—Triamcinolone—psoriasis	8.47e-05	0.000262	CcSEcCtD
Oxycodone—Nervous system disorder—Dexamethasone—psoriasis	8.46e-05	0.000261	CcSEcCtD
Oxycodone—Nervous system disorder—Betamethasone—psoriasis	8.46e-05	0.000261	CcSEcCtD
Oxycodone—Agitation—Prednisone—psoriasis	8.46e-05	0.000261	CcSEcCtD
Oxycodone—Tachycardia—Dexamethasone—psoriasis	8.42e-05	0.00026	CcSEcCtD
Oxycodone—Tachycardia—Betamethasone—psoriasis	8.42e-05	0.00026	CcSEcCtD
Oxycodone—Angioedema—Prednisone—psoriasis	8.41e-05	0.00026	CcSEcCtD
Oxycodone—Hypersensitivity—Cyclosporine—psoriasis	8.37e-05	0.000259	CcSEcCtD
Oxycodone—Dyspepsia—Triamcinolone—psoriasis	8.37e-05	0.000259	CcSEcCtD
Oxycodone—Nausea—Mycophenolic acid—psoriasis	8.34e-05	0.000258	CcSEcCtD
Oxycodone—Hyperhidrosis—Dexamethasone—psoriasis	8.34e-05	0.000258	CcSEcCtD
Oxycodone—Hyperhidrosis—Betamethasone—psoriasis	8.34e-05	0.000258	CcSEcCtD
Oxycodone—Feeling abnormal—Hydrocortisone—psoriasis	8.32e-05	0.000257	CcSEcCtD
Oxycodone—Malaise—Prednisone—psoriasis	8.3e-05	0.000256	CcSEcCtD
Oxycodone—Vertigo—Prednisone—psoriasis	8.27e-05	0.000255	CcSEcCtD
Oxycodone—Eye disorder—Methotrexate—psoriasis	8.26e-05	0.000255	CcSEcCtD
Oxycodone—Gastrointestinal pain—Hydrocortisone—psoriasis	8.25e-05	0.000255	CcSEcCtD
Oxycodone—Syncope—Prednisone—psoriasis	8.25e-05	0.000255	CcSEcCtD
Oxycodone—Tinnitus—Methotrexate—psoriasis	8.24e-05	0.000255	CcSEcCtD
Oxycodone—Anorexia—Dexamethasone—psoriasis	8.22e-05	0.000254	CcSEcCtD
Oxycodone—Anorexia—Betamethasone—psoriasis	8.22e-05	0.000254	CcSEcCtD
Oxycodone—Urticaria—Prednisolone—psoriasis	8.21e-05	0.000254	CcSEcCtD
Oxycodone—Cardiac disorder—Methotrexate—psoriasis	8.2e-05	0.000253	CcSEcCtD
Oxycodone—Fatigue—Triamcinolone—psoriasis	8.19e-05	0.000253	CcSEcCtD
Oxycodone—Hypersensitivity—Mycophenolate mofetil—psoriasis	8.16e-05	0.000252	CcSEcCtD
Oxycodone—Asthenia—Cyclosporine—psoriasis	8.15e-05	0.000252	CcSEcCtD
Oxycodone—Pain—Triamcinolone—psoriasis	8.13e-05	0.000251	CcSEcCtD
Oxycodone—Loss of consciousness—Prednisone—psoriasis	8.09e-05	0.00025	CcSEcCtD
Oxycodone—Hypotension—Betamethasone—psoriasis	8.06e-05	0.000249	CcSEcCtD
Oxycodone—Hypotension—Dexamethasone—psoriasis	8.06e-05	0.000249	CcSEcCtD
Oxycodone—Pruritus—Cyclosporine—psoriasis	8.03e-05	0.000248	CcSEcCtD
Oxycodone—Urticaria—Hydrocortisone—psoriasis	8.02e-05	0.000248	CcSEcCtD
Oxycodone—Angiopathy—Methotrexate—psoriasis	8.01e-05	0.000248	CcSEcCtD
Oxycodone—Immune system disorder—Methotrexate—psoriasis	7.98e-05	0.000247	CcSEcCtD
Oxycodone—Abdominal pain—Hydrocortisone—psoriasis	7.98e-05	0.000247	CcSEcCtD
Oxycodone—Body temperature increased—Hydrocortisone—psoriasis	7.98e-05	0.000247	CcSEcCtD
Oxycodone—Convulsion—Prednisone—psoriasis	7.97e-05	0.000246	CcSEcCtD
Oxycodone—Mediastinal disorder—Methotrexate—psoriasis	7.96e-05	0.000246	CcSEcCtD
Oxycodone—Asthenia—Mycophenolate mofetil—psoriasis	7.95e-05	0.000246	CcSEcCtD
Oxycodone—Chills—Methotrexate—psoriasis	7.93e-05	0.000245	CcSEcCtD
Oxycodone—Musculoskeletal discomfort—Betamethasone—psoriasis	7.86e-05	0.000243	CcSEcCtD
Oxycodone—Musculoskeletal discomfort—Dexamethasone—psoriasis	7.86e-05	0.000243	CcSEcCtD
Oxycodone—Pruritus—Mycophenolate mofetil—psoriasis	7.84e-05	0.000242	CcSEcCtD
Oxycodone—Arthralgia—Prednisone—psoriasis	7.83e-05	0.000242	CcSEcCtD
Oxycodone—Myalgia—Prednisone—psoriasis	7.83e-05	0.000242	CcSEcCtD
Oxycodone—Feeling abnormal—Triamcinolone—psoriasis	7.83e-05	0.000242	CcSEcCtD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.83e-05	0.00708	CbGpPWpGaD
Oxycodone—Anxiety—Prednisone—psoriasis	7.81e-05	0.000241	CcSEcCtD
Oxycodone—Insomnia—Betamethasone—psoriasis	7.8e-05	0.000241	CcSEcCtD
Oxycodone—Insomnia—Dexamethasone—psoriasis	7.8e-05	0.000241	CcSEcCtD
Oxycodone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	7.78e-05	0.00024	CcSEcCtD
Oxycodone—Diarrhoea—Cyclosporine—psoriasis	7.77e-05	0.00024	CcSEcCtD
Oxycodone—Paraesthesia—Betamethasone—psoriasis	7.74e-05	0.000239	CcSEcCtD
Oxycodone—Paraesthesia—Dexamethasone—psoriasis	7.74e-05	0.000239	CcSEcCtD
Oxycodone—Discomfort—Prednisone—psoriasis	7.74e-05	0.000239	CcSEcCtD
Oxycodone—Mental disorder—Methotrexate—psoriasis	7.74e-05	0.000239	CcSEcCtD
Oxycodone—Malnutrition—Methotrexate—psoriasis	7.69e-05	0.000238	CcSEcCtD
Oxycodone—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	7.68e-05	0.00695	CbGpPWpGaD
Oxycodone—Hypersensitivity—Prednisolone—psoriasis	7.61e-05	0.000235	CcSEcCtD
Oxycodone—Dyspepsia—Betamethasone—psoriasis	7.59e-05	0.000235	CcSEcCtD
Oxycodone—Dyspepsia—Dexamethasone—psoriasis	7.59e-05	0.000235	CcSEcCtD
Oxycodone—Diarrhoea—Mycophenolate mofetil—psoriasis	7.58e-05	0.000234	CcSEcCtD
Oxycodone—Urticaria—Triamcinolone—psoriasis	7.55e-05	0.000233	CcSEcCtD
Oxycodone—Dysgeusia—Methotrexate—psoriasis	7.53e-05	0.000233	CcSEcCtD
Oxycodone—Body temperature increased—Triamcinolone—psoriasis	7.51e-05	0.000232	CcSEcCtD
Oxycodone—Dizziness—Cyclosporine—psoriasis	7.51e-05	0.000232	CcSEcCtD
Oxycodone—Anaphylactic shock—Prednisone—psoriasis	7.51e-05	0.000232	CcSEcCtD
Oxycodone—Oedema—Prednisone—psoriasis	7.51e-05	0.000232	CcSEcCtD
Oxycodone—Decreased appetite—Betamethasone—psoriasis	7.5e-05	0.000232	CcSEcCtD
Oxycodone—Decreased appetite—Dexamethasone—psoriasis	7.5e-05	0.000232	CcSEcCtD
Oxycodone—Infection—Prednisone—psoriasis	7.46e-05	0.000231	CcSEcCtD
Oxycodone—Gastrointestinal disorder—Dexamethasone—psoriasis	7.44e-05	0.00023	CcSEcCtD
Oxycodone—Gastrointestinal disorder—Betamethasone—psoriasis	7.44e-05	0.00023	CcSEcCtD
Oxycodone—Back pain—Methotrexate—psoriasis	7.44e-05	0.00023	CcSEcCtD
Oxycodone—Hypersensitivity—Hydrocortisone—psoriasis	7.44e-05	0.00023	CcSEcCtD
Oxycodone—Fatigue—Betamethasone—psoriasis	7.43e-05	0.00023	CcSEcCtD
Oxycodone—Fatigue—Dexamethasone—psoriasis	7.43e-05	0.00023	CcSEcCtD
Oxycodone—Shock—Prednisone—psoriasis	7.39e-05	0.000228	CcSEcCtD
Oxycodone—Pain—Dexamethasone—psoriasis	7.37e-05	0.000228	CcSEcCtD
Oxycodone—Pain—Betamethasone—psoriasis	7.37e-05	0.000228	CcSEcCtD
Oxycodone—Nervous system disorder—Prednisone—psoriasis	7.36e-05	0.000228	CcSEcCtD
Oxycodone—Tachycardia—Prednisone—psoriasis	7.33e-05	0.000226	CcSEcCtD
Oxycodone—Dizziness—Mycophenolate mofetil—psoriasis	7.33e-05	0.000226	CcSEcCtD
Oxycodone—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	7.3e-05	0.0066	CbGpPWpGaD
Oxycodone—Skin disorder—Prednisone—psoriasis	7.29e-05	0.000225	CcSEcCtD
Oxycodone—Hyperhidrosis—Prednisone—psoriasis	7.26e-05	0.000224	CcSEcCtD
Oxycodone—Asthenia—Hydrocortisone—psoriasis	7.24e-05	0.000224	CcSEcCtD
Oxycodone—Vomiting—Cyclosporine—psoriasis	7.22e-05	0.000223	CcSEcCtD
Oxycodone—CYP2D6—Biological oxidations—CYP2S1—psoriasis	7.21e-05	0.00652	CbGpPWpGaD
Oxycodone—Rash—Cyclosporine—psoriasis	7.16e-05	0.000221	CcSEcCtD
Oxycodone—Anorexia—Prednisone—psoriasis	7.16e-05	0.000221	CcSEcCtD
Oxycodone—Dermatitis—Cyclosporine—psoriasis	7.15e-05	0.000221	CcSEcCtD
Oxycodone—Pruritus—Hydrocortisone—psoriasis	7.14e-05	0.000221	CcSEcCtD
Oxycodone—Ill-defined disorder—Methotrexate—psoriasis	7.13e-05	0.00022	CcSEcCtD
Oxycodone—Headache—Cyclosporine—psoriasis	7.11e-05	0.00022	CcSEcCtD
Oxycodone—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	7.11e-05	0.00643	CbGpPWpGaD
Oxycodone—Anaemia—Methotrexate—psoriasis	7.11e-05	0.00022	CcSEcCtD
Oxycodone—Feeling abnormal—Betamethasone—psoriasis	7.11e-05	0.00022	CcSEcCtD
Oxycodone—Feeling abnormal—Dexamethasone—psoriasis	7.11e-05	0.00022	CcSEcCtD
Oxycodone—Gastrointestinal pain—Dexamethasone—psoriasis	7.05e-05	0.000218	CcSEcCtD
Oxycodone—Gastrointestinal pain—Betamethasone—psoriasis	7.05e-05	0.000218	CcSEcCtD
Oxycodone—Vomiting—Mycophenolate mofetil—psoriasis	7.04e-05	0.000218	CcSEcCtD
Oxycodone—Hypersensitivity—Triamcinolone—psoriasis	7e-05	0.000216	CcSEcCtD
Oxycodone—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	6.99e-05	0.00632	CbGpPWpGaD
Oxycodone—Rash—Mycophenolate mofetil—psoriasis	6.99e-05	0.000216	CcSEcCtD
Oxycodone—Dermatitis—Mycophenolate mofetil—psoriasis	6.98e-05	0.000216	CcSEcCtD
Oxycodone—Headache—Mycophenolate mofetil—psoriasis	6.94e-05	0.000214	CcSEcCtD
Oxycodone—Malaise—Methotrexate—psoriasis	6.93e-05	0.000214	CcSEcCtD
Oxycodone—Vertigo—Methotrexate—psoriasis	6.91e-05	0.000214	CcSEcCtD
Oxycodone—Diarrhoea—Hydrocortisone—psoriasis	6.91e-05	0.000213	CcSEcCtD
Oxycodone—Leukopenia—Methotrexate—psoriasis	6.88e-05	0.000213	CcSEcCtD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	6.87e-05	0.00621	CbGpPWpGaD
Oxycodone—Urticaria—Dexamethasone—psoriasis	6.85e-05	0.000212	CcSEcCtD
Oxycodone—Urticaria—Betamethasone—psoriasis	6.85e-05	0.000212	CcSEcCtD
Oxycodone—Musculoskeletal discomfort—Prednisone—psoriasis	6.84e-05	0.000211	CcSEcCtD
Oxycodone—Dizziness—Prednisolone—psoriasis	6.83e-05	0.000211	CcSEcCtD
Oxycodone—Asthenia—Triamcinolone—psoriasis	6.82e-05	0.000211	CcSEcCtD
Oxycodone—Abdominal pain—Betamethasone—psoriasis	6.82e-05	0.000211	CcSEcCtD
Oxycodone—Body temperature increased—Dexamethasone—psoriasis	6.82e-05	0.000211	CcSEcCtD
Oxycodone—Abdominal pain—Dexamethasone—psoriasis	6.82e-05	0.000211	CcSEcCtD
Oxycodone—Body temperature increased—Betamethasone—psoriasis	6.82e-05	0.000211	CcSEcCtD
Oxycodone—Insomnia—Prednisone—psoriasis	6.79e-05	0.00021	CcSEcCtD
Oxycodone—Nausea—Cyclosporine—psoriasis	6.75e-05	0.000208	CcSEcCtD
Oxycodone—Paraesthesia—Prednisone—psoriasis	6.74e-05	0.000208	CcSEcCtD
Oxycodone—Pruritus—Triamcinolone—psoriasis	6.72e-05	0.000208	CcSEcCtD
Oxycodone—Cough—Methotrexate—psoriasis	6.71e-05	0.000207	CcSEcCtD
Oxycodone—Dizziness—Hydrocortisone—psoriasis	6.67e-05	0.000206	CcSEcCtD
Oxycodone—Convulsion—Methotrexate—psoriasis	6.66e-05	0.000206	CcSEcCtD
Oxycodone—Dyspepsia—Prednisone—psoriasis	6.61e-05	0.000204	CcSEcCtD
Oxycodone—Nausea—Mycophenolate mofetil—psoriasis	6.58e-05	0.000203	CcSEcCtD
Oxycodone—Chest pain—Methotrexate—psoriasis	6.55e-05	0.000202	CcSEcCtD
Oxycodone—Arthralgia—Methotrexate—psoriasis	6.55e-05	0.000202	CcSEcCtD
Oxycodone—Myalgia—Methotrexate—psoriasis	6.55e-05	0.000202	CcSEcCtD
Oxycodone—Decreased appetite—Prednisone—psoriasis	6.53e-05	0.000202	CcSEcCtD
Oxycodone—Rash—Prednisolone—psoriasis	6.52e-05	0.000201	CcSEcCtD
Oxycodone—Dermatitis—Prednisolone—psoriasis	6.51e-05	0.000201	CcSEcCtD
Oxycodone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.5e-05	0.000201	CcSEcCtD
Oxycodone—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	6.49e-05	0.00587	CbGpPWpGaD
Oxycodone—Fatigue—Prednisone—psoriasis	6.47e-05	0.0002	CcSEcCtD
Oxycodone—Headache—Prednisolone—psoriasis	6.47e-05	0.0002	CcSEcCtD
Oxycodone—Discomfort—Methotrexate—psoriasis	6.47e-05	0.0002	CcSEcCtD
Oxycodone—Constipation—Prednisone—psoriasis	6.42e-05	0.000198	CcSEcCtD
Oxycodone—Vomiting—Hydrocortisone—psoriasis	6.42e-05	0.000198	CcSEcCtD
Oxycodone—Rash—Hydrocortisone—psoriasis	6.36e-05	0.000197	CcSEcCtD
Oxycodone—Dermatitis—Hydrocortisone—psoriasis	6.36e-05	0.000196	CcSEcCtD
Oxycodone—Confusional state—Methotrexate—psoriasis	6.33e-05	0.000196	CcSEcCtD
Oxycodone—Headache—Hydrocortisone—psoriasis	6.32e-05	0.000195	CcSEcCtD
Oxycodone—Dizziness—Triamcinolone—psoriasis	6.28e-05	0.000194	CcSEcCtD
Oxycodone—Anaphylactic shock—Methotrexate—psoriasis	6.28e-05	0.000194	CcSEcCtD
Oxycodone—Infection—Methotrexate—psoriasis	6.23e-05	0.000193	CcSEcCtD
Oxycodone—Feeling abnormal—Prednisone—psoriasis	6.19e-05	0.000191	CcSEcCtD
Oxycodone—Asthenia—Betamethasone—psoriasis	6.19e-05	0.000191	CcSEcCtD
Oxycodone—Asthenia—Dexamethasone—psoriasis	6.19e-05	0.000191	CcSEcCtD
Oxycodone—Nervous system disorder—Methotrexate—psoriasis	6.15e-05	0.00019	CcSEcCtD
Oxycodone—Gastrointestinal pain—Prednisone—psoriasis	6.14e-05	0.00019	CcSEcCtD
Oxycodone—Nausea—Prednisolone—psoriasis	6.14e-05	0.00019	CcSEcCtD
Oxycodone—Pruritus—Betamethasone—psoriasis	6.1e-05	0.000189	CcSEcCtD
Oxycodone—Pruritus—Dexamethasone—psoriasis	6.1e-05	0.000189	CcSEcCtD
Oxycodone—Skin disorder—Methotrexate—psoriasis	6.1e-05	0.000188	CcSEcCtD
Oxycodone—Hyperhidrosis—Methotrexate—psoriasis	6.07e-05	0.000187	CcSEcCtD
Oxycodone—Vomiting—Triamcinolone—psoriasis	6.04e-05	0.000187	CcSEcCtD
Oxycodone—Nausea—Hydrocortisone—psoriasis	6e-05	0.000185	CcSEcCtD
Oxycodone—Rash—Triamcinolone—psoriasis	5.99e-05	0.000185	CcSEcCtD
Oxycodone—Dermatitis—Triamcinolone—psoriasis	5.99e-05	0.000185	CcSEcCtD
Oxycodone—Anorexia—Methotrexate—psoriasis	5.98e-05	0.000185	CcSEcCtD
Oxycodone—Urticaria—Prednisone—psoriasis	5.97e-05	0.000184	CcSEcCtD
Oxycodone—OPRD1—GPCR ligand binding—CCL20—psoriasis	5.96e-05	0.00539	CbGpPWpGaD
Oxycodone—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	5.96e-05	0.00539	CbGpPWpGaD
Oxycodone—Headache—Triamcinolone—psoriasis	5.95e-05	0.000184	CcSEcCtD
Oxycodone—Abdominal pain—Prednisone—psoriasis	5.94e-05	0.000183	CcSEcCtD
Oxycodone—Body temperature increased—Prednisone—psoriasis	5.94e-05	0.000183	CcSEcCtD
Oxycodone—Diarrhoea—Dexamethasone—psoriasis	5.9e-05	0.000182	CcSEcCtD
Oxycodone—Diarrhoea—Betamethasone—psoriasis	5.9e-05	0.000182	CcSEcCtD
Oxycodone—OPRD1—Signaling by GPCR—HCAR2—psoriasis	5.89e-05	0.00533	CbGpPWpGaD
Oxycodone—Hypotension—Methotrexate—psoriasis	5.86e-05	0.000181	CcSEcCtD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	5.8e-05	0.00525	CbGpPWpGaD
Oxycodone—Musculoskeletal discomfort—Methotrexate—psoriasis	5.72e-05	0.000177	CcSEcCtD
Oxycodone—Dizziness—Dexamethasone—psoriasis	5.7e-05	0.000176	CcSEcCtD
Oxycodone—Dizziness—Betamethasone—psoriasis	5.7e-05	0.000176	CcSEcCtD
Oxycodone—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	5.69e-05	0.00515	CbGpPWpGaD
Oxycodone—Insomnia—Methotrexate—psoriasis	5.68e-05	0.000175	CcSEcCtD
Oxycodone—Nausea—Triamcinolone—psoriasis	5.64e-05	0.000174	CcSEcCtD
Oxycodone—Paraesthesia—Methotrexate—psoriasis	5.64e-05	0.000174	CcSEcCtD
Oxycodone—Dyspnoea—Methotrexate—psoriasis	5.6e-05	0.000173	CcSEcCtD
Oxycodone—Somnolence—Methotrexate—psoriasis	5.58e-05	0.000172	CcSEcCtD
Oxycodone—Hypersensitivity—Prednisone—psoriasis	5.53e-05	0.000171	CcSEcCtD
Oxycodone—Dyspepsia—Methotrexate—psoriasis	5.52e-05	0.000171	CcSEcCtD
Oxycodone—Vomiting—Dexamethasone—psoriasis	5.48e-05	0.000169	CcSEcCtD
Oxycodone—Vomiting—Betamethasone—psoriasis	5.48e-05	0.000169	CcSEcCtD
Oxycodone—Decreased appetite—Methotrexate—psoriasis	5.46e-05	0.000169	CcSEcCtD
Oxycodone—Rash—Betamethasone—psoriasis	5.44e-05	0.000168	CcSEcCtD
Oxycodone—Rash—Dexamethasone—psoriasis	5.44e-05	0.000168	CcSEcCtD
Oxycodone—Dermatitis—Dexamethasone—psoriasis	5.43e-05	0.000168	CcSEcCtD
Oxycodone—Dermatitis—Betamethasone—psoriasis	5.43e-05	0.000168	CcSEcCtD
Oxycodone—Gastrointestinal disorder—Methotrexate—psoriasis	5.42e-05	0.000167	CcSEcCtD
Oxycodone—Fatigue—Methotrexate—psoriasis	5.41e-05	0.000167	CcSEcCtD
Oxycodone—Headache—Dexamethasone—psoriasis	5.4e-05	0.000167	CcSEcCtD
Oxycodone—Headache—Betamethasone—psoriasis	5.4e-05	0.000167	CcSEcCtD
Oxycodone—Asthenia—Prednisone—psoriasis	5.39e-05	0.000167	CcSEcCtD
Oxycodone—Pain—Methotrexate—psoriasis	5.37e-05	0.000166	CcSEcCtD
Oxycodone—Pruritus—Prednisone—psoriasis	5.31e-05	0.000164	CcSEcCtD
Oxycodone—OPRK1—GPCR ligand binding—CCL20—psoriasis	5.23e-05	0.00473	CbGpPWpGaD
Oxycodone—Feeling abnormal—Methotrexate—psoriasis	5.17e-05	0.00016	CcSEcCtD
Oxycodone—OPRK1—Signaling by GPCR—HCAR2—psoriasis	5.17e-05	0.00467	CbGpPWpGaD
Oxycodone—Diarrhoea—Prednisone—psoriasis	5.14e-05	0.000159	CcSEcCtD
Oxycodone—Gastrointestinal pain—Methotrexate—psoriasis	5.13e-05	0.000159	CcSEcCtD
Oxycodone—Nausea—Dexamethasone—psoriasis	5.12e-05	0.000158	CcSEcCtD
Oxycodone—Nausea—Betamethasone—psoriasis	5.12e-05	0.000158	CcSEcCtD
Oxycodone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.03e-05	0.00455	CbGpPWpGaD
Oxycodone—Urticaria—Methotrexate—psoriasis	4.99e-05	0.000154	CcSEcCtD
Oxycodone—Dizziness—Prednisone—psoriasis	4.97e-05	0.000153	CcSEcCtD
Oxycodone—Body temperature increased—Methotrexate—psoriasis	4.96e-05	0.000153	CcSEcCtD
Oxycodone—Abdominal pain—Methotrexate—psoriasis	4.96e-05	0.000153	CcSEcCtD
Oxycodone—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	4.81e-05	0.00435	CbGpPWpGaD
Oxycodone—Vomiting—Prednisone—psoriasis	4.77e-05	0.000148	CcSEcCtD
Oxycodone—Rash—Prednisone—psoriasis	4.73e-05	0.000146	CcSEcCtD
Oxycodone—Dermatitis—Prednisone—psoriasis	4.73e-05	0.000146	CcSEcCtD
Oxycodone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.71e-05	0.00426	CbGpPWpGaD
Oxycodone—Headache—Prednisone—psoriasis	4.7e-05	0.000145	CcSEcCtD
Oxycodone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	4.65e-05	0.00421	CbGpPWpGaD
Oxycodone—Hypersensitivity—Methotrexate—psoriasis	4.62e-05	0.000143	CcSEcCtD
Oxycodone—Asthenia—Methotrexate—psoriasis	4.5e-05	0.000139	CcSEcCtD
Oxycodone—Nausea—Prednisone—psoriasis	4.46e-05	0.000138	CcSEcCtD
Oxycodone—Pruritus—Methotrexate—psoriasis	4.44e-05	0.000137	CcSEcCtD
Oxycodone—OPRM1—GPCR ligand binding—CCL20—psoriasis	4.42e-05	0.004	CbGpPWpGaD
Oxycodone—OPRM1—TCR Signaling Pathway—CD4—psoriasis	4.41e-05	0.00399	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—HCAR2—psoriasis	4.37e-05	0.00395	CbGpPWpGaD
Oxycodone—Diarrhoea—Methotrexate—psoriasis	4.29e-05	0.000133	CcSEcCtD
Oxycodone—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	4.16e-05	0.00376	CbGpPWpGaD
Oxycodone—Dizziness—Methotrexate—psoriasis	4.15e-05	0.000128	CcSEcCtD
Oxycodone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4.07e-05	0.00368	CbGpPWpGaD
Oxycodone—Vomiting—Methotrexate—psoriasis	3.99e-05	0.000123	CcSEcCtD
Oxycodone—Rash—Methotrexate—psoriasis	3.96e-05	0.000122	CcSEcCtD
Oxycodone—Dermatitis—Methotrexate—psoriasis	3.95e-05	0.000122	CcSEcCtD
Oxycodone—OPRM1—TCR Signaling Pathway—JUN—psoriasis	3.95e-05	0.00357	CbGpPWpGaD
Oxycodone—Headache—Methotrexate—psoriasis	3.93e-05	0.000122	CcSEcCtD
Oxycodone—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	3.8e-05	0.00344	CbGpPWpGaD
Oxycodone—Nausea—Methotrexate—psoriasis	3.73e-05	0.000115	CcSEcCtD
Oxycodone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.51e-05	0.00317	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—HCAR2—psoriasis	3.48e-05	0.00315	CbGpPWpGaD
Oxycodone—OPRD1—GPCR downstream signaling—CCL20—psoriasis	3.37e-05	0.00305	CbGpPWpGaD
Oxycodone—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	3.15e-05	0.00285	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CCL20—psoriasis	3.06e-05	0.00277	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—HCAR2—psoriasis	3.05e-05	0.00276	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—TAGAP—psoriasis	3.02e-05	0.00273	CbGpPWpGaD
Oxycodone—OPRK1—GPCR downstream signaling—CCL20—psoriasis	2.95e-05	0.00267	CbGpPWpGaD
Oxycodone—CYP3A7—Metabolism—NDUFA5—psoriasis	2.82e-05	0.00255	CbGpPWpGaD
Oxycodone—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	2.76e-05	0.0025	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—CCL20—psoriasis	2.68e-05	0.00243	CbGpPWpGaD
Oxycodone—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	2.66e-05	0.00241	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—TAGAP—psoriasis	2.65e-05	0.00239	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—HCAR2—psoriasis	2.58e-05	0.00233	CbGpPWpGaD
Oxycodone—OPRM1—GPCR downstream signaling—CCL20—psoriasis	2.5e-05	0.00226	CbGpPWpGaD
Oxycodone—CYP3A7—Metabolism—CYP2S1—psoriasis	2.4e-05	0.00217	CbGpPWpGaD
Oxycodone—OPRM1—TCR Signaling Pathway—IL6—psoriasis	2.39e-05	0.00216	CbGpPWpGaD
Oxycodone—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	2.34e-05	0.00211	CbGpPWpGaD
Oxycodone—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	2.33e-05	0.00211	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CCL20—psoriasis	2.27e-05	0.00205	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—TAGAP—psoriasis	2.24e-05	0.00202	CbGpPWpGaD
Oxycodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.11e-05	0.00191	CbGpPWpGaD
Oxycodone—CYP3A5—Metabolism—NDUFA5—psoriasis	2.04e-05	0.00184	CbGpPWpGaD
Oxycodone—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	1.97e-05	0.00178	CbGpPWpGaD
Oxycodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.85e-05	0.00168	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CCL20—psoriasis	1.81e-05	0.00163	CbGpPWpGaD
Oxycodone—CYP3A5—Metabolism—CYP2S1—psoriasis	1.73e-05	0.00157	CbGpPWpGaD
Oxycodone—OPRD1—GPCR ligand binding—CXCL8—psoriasis	1.61e-05	0.00146	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CCL20—psoriasis	1.59e-05	0.00143	CbGpPWpGaD
Oxycodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.57e-05	0.00142	CbGpPWpGaD
Oxycodone—CYP2D6—Metabolism—NDUFA5—psoriasis	1.45e-05	0.00131	CbGpPWpGaD
Oxycodone—OPRK1—GPCR ligand binding—CXCL8—psoriasis	1.41e-05	0.00128	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CCL20—psoriasis	1.34e-05	0.00121	CbGpPWpGaD
Oxycodone—CYP2D6—Metabolism—CYP2S1—psoriasis	1.23e-05	0.00112	CbGpPWpGaD
Oxycodone—OPRM1—GPCR ligand binding—CXCL8—psoriasis	1.19e-05	0.00108	CbGpPWpGaD
Oxycodone—CYP3A7—Metabolism—CARM1—psoriasis	1.17e-05	0.00106	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—SOCS1—psoriasis	9.95e-06	0.0009	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—TYK2—psoriasis	9.49e-06	0.000858	CbGpPWpGaD
Oxycodone—CYP3A4—Metabolism—NDUFA5—psoriasis	9.48e-06	0.000858	CbGpPWpGaD
Oxycodone—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	9.1e-06	0.000823	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—SOCS1—psoriasis	8.73e-06	0.000789	CbGpPWpGaD
Oxycodone—CYP3A5—Metabolism—CARM1—psoriasis	8.47e-06	0.000766	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—TYK2—psoriasis	8.32e-06	0.000753	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—CXCL8—psoriasis	8.26e-06	0.000747	CbGpPWpGaD
Oxycodone—CYP3A4—Metabolism—CYP2S1—psoriasis	8.06e-06	0.000729	CbGpPWpGaD
Oxycodone—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	7.98e-06	0.000722	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—SOCS1—psoriasis	7.38e-06	0.000667	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—APOE—psoriasis	7.35e-06	0.000664	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—LEP—psoriasis	7.35e-06	0.000664	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—CXCL8—psoriasis	7.25e-06	0.000655	CbGpPWpGaD
Oxycodone—CYP3A7—Metabolism—CAT—psoriasis	7.21e-06	0.000652	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—TYK2—psoriasis	7.03e-06	0.000636	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—NFKBIA—psoriasis	6.84e-06	0.000619	CbGpPWpGaD
Oxycodone—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	6.74e-06	0.00061	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—APOE—psoriasis	6.44e-06	0.000583	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—LEP—psoriasis	6.44e-06	0.000583	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—CXCL8—psoriasis	6.12e-06	0.000554	CbGpPWpGaD
Oxycodone—CYP2D6—Metabolism—CARM1—psoriasis	6.02e-06	0.000545	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—NFKBIA—psoriasis	6e-06	0.000543	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—TYK2—psoriasis	5.61e-06	0.000507	CbGpPWpGaD
Oxycodone—CYP3A7—Metabolism—APOE—psoriasis	5.6e-06	0.000506	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—LEP—psoriasis	5.44e-06	0.000492	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—APOE—psoriasis	5.44e-06	0.000492	CbGpPWpGaD
Oxycodone—CYP3A5—Metabolism—CAT—psoriasis	5.21e-06	0.000471	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—NFKBIA—psoriasis	5.07e-06	0.000459	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—TYK2—psoriasis	4.92e-06	0.000445	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—CXCL8—psoriasis	4.88e-06	0.000441	CbGpPWpGaD
Oxycodone—CYP3A7—Metabolism—PPARG—psoriasis	4.88e-06	0.000441	CbGpPWpGaD
Oxycodone—OPRD1—Signaling by GPCR—IL6—psoriasis	4.64e-06	0.00042	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—JUN—psoriasis	4.54e-06	0.00041	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—NFKB1—psoriasis	4.37e-06	0.000395	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—CXCL8—psoriasis	4.28e-06	0.000387	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—TYK2—psoriasis	4.15e-06	0.000376	CbGpPWpGaD
Oxycodone—OPRK1—Signaling by GPCR—IL6—psoriasis	4.07e-06	0.000368	CbGpPWpGaD
Oxycodone—CYP3A5—Metabolism—APOE—psoriasis	4.05e-06	0.000366	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—JUN—psoriasis	3.98e-06	0.00036	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—VEGFA—psoriasis	3.96e-06	0.000359	CbGpPWpGaD
Oxycodone—CYP3A4—Metabolism—CARM1—psoriasis	3.94e-06	0.000356	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—STAT3—psoriasis	3.93e-06	0.000355	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—NFKB1—psoriasis	3.83e-06	0.000346	CbGpPWpGaD
Oxycodone—CYP2D6—Metabolism—CAT—psoriasis	3.7e-06	0.000335	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—CXCL8—psoriasis	3.62e-06	0.000327	CbGpPWpGaD
Oxycodone—CYP3A5—Metabolism—PPARG—psoriasis	3.53e-06	0.000319	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—VEGFA—psoriasis	3.48e-06	0.000314	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—STAT3—psoriasis	3.44e-06	0.000311	CbGpPWpGaD
Oxycodone—OPRM1—Signaling by GPCR—IL6—psoriasis	3.44e-06	0.000311	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—JUN—psoriasis	3.36e-06	0.000304	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—NFKB1—psoriasis	3.24e-06	0.000293	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—TP53—psoriasis	3e-06	0.000271	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—VEGFA—psoriasis	2.94e-06	0.000266	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—STAT3—psoriasis	2.91e-06	0.000263	CbGpPWpGaD
Oxycodone—CYP2D6—Metabolism—APOE—psoriasis	2.88e-06	0.00026	CbGpPWpGaD
Oxycodone—OPRD1—Signaling Pathways—IL6—psoriasis	2.74e-06	0.000248	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—TP53—psoriasis	2.63e-06	0.000238	CbGpPWpGaD
Oxycodone—CYP2D6—Metabolism—PPARG—psoriasis	2.51e-06	0.000227	CbGpPWpGaD
Oxycodone—CYP3A4—Metabolism—CAT—psoriasis	2.42e-06	0.000219	CbGpPWpGaD
Oxycodone—OPRK1—Signaling Pathways—IL6—psoriasis	2.4e-06	0.000217	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—TP53—psoriasis	2.22e-06	0.000201	CbGpPWpGaD
Oxycodone—OPRM1—Signaling Pathways—IL6—psoriasis	2.03e-06	0.000184	CbGpPWpGaD
Oxycodone—CYP3A4—Metabolism—APOE—psoriasis	1.88e-06	0.00017	CbGpPWpGaD
Oxycodone—CYP3A4—Metabolism—PPARG—psoriasis	1.64e-06	0.000148	CbGpPWpGaD
